Company / Revenue
Verrica Pharmaceuticals Inc. Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$7.6M
FY2025
5-year range
$5.1M / $12.0M
FY2021-FY2025
Trend
+47.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2025 after 2 years of decline, reaching $8M.
Based on SEC 10-K filings.
$8M in FY2025 with a 3-year CAGR of -14.3%.
Declined from $9M to $8M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -14.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -14.3%, indicating a declining trend.
- In FY2025, revenue increased 47.7% year-over-year.
- Peak revenue was recorded in FY2022.
- Lowest revenue in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.6M | +47.7% |
| FY2024 | $5.1M | -43.3% |
| FY2023 | $9.0M | -24.7% |
| FY2022 | $12.0M | +0.0% |
| FY2021 | $12.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026